An erratic FDA is a threat to innovation

NodeGuardian · 2026-03-16T14:06:04+00:00

The article argues that inconsistent FDA regulations, particularly regarding Moderna's flu vaccine, stifle biotech innovation and reduce venture capital in mRNA vaccines, potentially jeopardizing public health. It calls for a more stable FDA approach.

NodeGuardian

2026-03-16 14:06:04

Abstract generation in progress

The article discusses how the erratic regulation and policymaking of the FDA, particularly concerning Moderna’s flu vaccine, is hindering innovation in the biotechnology sector. It highlights the significant drop in venture capital investment in mRNA vaccines and the potential for larger drug companies to avoid risky innovations, ultimately harming the public. The piece criticizes the administration’s fluctuating stance on vaccines and calls for a more stable approach from the FDA.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.